HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional) (350837)

US Dept. of Health & Human Services: National Institutes of Health (NIH)

View website Save this grant

Next deadline: May 7, 2024

Later deadlines: May 24, 2024, Sep 7, 2024, Sep 24, 2024, Jan 7, 2025, Jan 24, 2025, May 7, 2025, May 23, 2025, Sep 7, 2025, Sep 24, 2025, Jan 7, 2026, Jan 23, 2026, May 7, 2026, May 22, 2026, Sep 7, 2026, Sep 24, 2026, Jan 7, 2027

Grant amount: Unspecified amount

Fields of work: Chronic / Acute Pain Pharmacology

Applicant type: Nonprofit, Government Entity, Indigenous Group, For-Profit Business

Funding uses: Research

Location of project: United States, American Samoa, Guam, Northern Mariana Islands, Puerto Rico Show all

Location of residency: Anywhere in the world


NOTE: Optional but encouraged Letters of Intent are due 30 days prior to a Full Proposal submission. The following full proposal deadlines apply to standard grant applications (due by 5:00 pm  local time of applicant organization):

  • January 24, 2024
  • May 24, 2024
  • September 24, 2024
  • January 24, 2025
  • May 23, 2025
  • September 24, 2025
  • January 23, 2026
  • May 22, 2026
  • September 24, 2026

Optional but encouraged Letters of Intent are due 30 days prior to a Full Proposal submission. The following full proposal deadlines apply to AIDS-related grant applications (due by 5:00 pm local time of applicant organization): 

  • May 7, 2024
  • September 7, 2024
  • January 7, 2025
  • May 7, 2025
  • September 7, 2025
  • January 7, 2026
  • May 7, 2026
  • September 7, 2026
  • January 7, 2027

Reissue of RFA-NS-20-010: The purpose of this funding opportunity announcement (FOA) is to support preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics to treat pain. The goal of the program is to accelerate the optimization and development of promising small molecule and biologic hits/leads towards clinical trials. Applicants must have a promising hit/lead, robust biological rationale for the intended approach, and identified assays for optimization of the agent. The scope of this program includes optimization and early development activities, IND-enabling studies, and assembly of Investigational New Drug (IND) application. This is a milestone-driven phased cooperative agreement program involving participation of NIH program staff in the development of the project plan and monitoring of research progress.

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.

US Dept. of Health & Human Services: National Institutes of Health (NIH)

Your history with this funder
No saved opportunities from this funder yet
Save this opportunity to add notes...
Save this opportunity to add contacts...

Other Funding Opportunities from Us Dept. Of Health & Human Services: National Institutes Of Health (Nih)

Don't miss out on other good fit funders!

Get personalized grant recommendations, tracking and more by creating a free 14-day account.

No credit card required.
instrumentl testimonial face

"Winning 30% more grants thanks to Instrumentl was a huge morale boost. My confidence continues to grow."

Linda Rucker, Grant Writer

This page was last reviewed November 03, 2023 and last updated November 03, 2023